You are hereDecember 13, 2018
What’s the Stem Cells Buzz this Week? - Letter to the Editor, GPCR boost to Pluripotency, Platelet Engrafting Progenitors, and Generating Dopaminergic Neurons!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Letter to the Editor – Reply to “Long‐Term Engraftment of Myoblasts in a Human Infarcted Heart”
In a Letter the Editor, Daniel Skuk and Jacques P. Tremblay (Research Center of the CHU de Quebec, Quebec, Canada) reply to a recent clinical report in STEM CELLS Translational Medicine. In this letter, the team wished to highlight the importance of the report findings (the persistence of myotubes in an infarct area 16 years after injection) towards a potential treatment of skeletal muscle degenerative disorders, including Duchenne muscular dystrophy. For more information on how myotube persistence in this patient may be a “stimulant for the field of regenerative medicine in the skeletal muscle”, see STEM CELLS Translational Medicine now!
The Role of the EDG5 G Protein-coupled Receptor Effector in Pluripotency
A recent study from the lab of Majlinda Lako (Newcastle University, Newcastle, UK) recently assessed for critical factors involved in the initiation phase of reprogramming to pluripotency via a high‐throughput short interfering RNA screening assay. Neganova et al. highlighted six G protein-coupled receptors (GPCRs) as effectors during early programming and examined the role for one of these effectors, EDG5 (S1P2). Interestingly, EDG5 downregulation in hESCs or during the initiation period of iPSC reprogramming inhibited maintenance/attainment of pluripotent colonies due to defects in cytoskeleton organization and focal adhesions. For more on a brand new pluripotency-associated factor, head over to STEM CELLS now!
Osteoblast Condition Medium Promotes Platelet Engrafting Progenitors
Previous studies established that osteoblast condition medium (OCM) could enhance the ability of blood progenitors to boost cell growth and increase levels of human platelets (hPLT) in transplanted mice. Now, a STEM CELLS report from the group of Nicolas Pineault (Canadian Blood Services, Ottawa, Canada) demonstrates that OCM strongly modulates the growth of umbilical cord blood stem and progenitor cells through activation of insulin‐like growth factor‐1 receptor and the subsequent activation of the beta‐catenin/TCF transcriptional activation complex. Overall, Abu‐Khader et al. propose that OCM-derived factors can significantly enhance the platelet engrafting activity of progenitors in culture.
Systematic Evaluation of Protocols to Generate Dopaminergic Neurons
With each passing week, another differentiation protocol for an already described cell type reaches publication; yet, these methodologies rarely see reuse beyond the reporting laboratory. To discover why, Rebecca Marton and John P. A. Ioannidis (Stanford University, Stanford, California, USA) systematically evaluated over 150 publications (2004‐2017) that differentiated human stem cells into dopaminergic neurons. The duo established that of the 74 novel or modified protocols developed, 65% were never employed again in subsequent studies; furthermore, they discovered improvement over time in the yield of neuron production, but not in yield of dopaminergic neurons or time required for differentiating neurons. To discover how to consider the effectiveness and utility of newly developed protocols, head over to STEM CELLS Translational Medicine.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!